Company intelligence / Profile preview
Labatec Pharma
Geneva, Geneva, Switzerlandlabatecpharma.com ↗
- Ownership
- Private
- Employees
- ~139
- Development stage
- Commercial
01
Overview
Labatec Pharma has a commercial portfolio of over 65–100 products across hospital and retail sectors in Europe and emerging markets. The company supplies critical anti-tuberculosis drugs such as ethambutol ("Myambutol"), rifampicine ("rifampicin"), pyrazinamide and isoniazid—some under assessment by the World Health Organization for prequalification. These are listed on the Global Fund Anti-TB list of pharmaceutical suppliers. The company also manufactures its own musculo-skeletal and TB treatments in the EU.
- Therapeutic areas
- RheumatologyOphthalmologyOtherWomen's HealthOncologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Supplies to Swiss hospitals/pharmacies for TB drugsListed supplier to Global Fund Anti-TB program
Beyond the preview
Go deeper on Labatec Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Labatec Pharma.